{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:24:37Z","timestamp":1783607077671,"version":"3.55.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41409-026-02872-7","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:57:06Z","timestamp":1778237826000},"page":"816-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-5090","authenticated-orcid":false,"given":"Mingyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieya","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-8310","authenticated-orcid":false,"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-6063","authenticated-orcid":false,"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2872_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00649-y","volume":"12","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Huang G, Cai X, Liu Y, Qian B, Li D. Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021. Biomark Res. 2024;12:101.","journal-title":"Biomark Res"},{"key":"2872_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","volume":"9","author":"Y Dong","year":"2020","unstructured":"Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14.","journal-title":"Exp Hematol Oncol"},{"key":"2872_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","volume":"10","author":"CR Cogle","year":"2015","unstructured":"Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10:272\u201381.","journal-title":"Curr Hematol Malig Rep"},{"key":"2872_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.respe.2015.12.017","volume":"64","author":"S Le Guyader-Peyrou","year":"2016","unstructured":"Le Guyader-Peyrou S, Belot A, Maynadie M, Binder-Foucard F, Remontet L, Troussard X, et al. Cancer incidence in France over the 1980-2012 period: Hematological malignancies. Rev Epidemiol Sant\u00e9 Publique. 2016;64:103\u201312.","journal-title":"Rev Epidemiol Sant\u00e9 Publique"},{"key":"2872_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","volume":"27","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997\u20139.","journal-title":"Leukemia"},{"key":"2872_CR6","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1016\/S2352-3026(21)00231-3","volume":"8","author":"VE Kennedy","year":"2021","unstructured":"Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021;8:e853\u2013e61.","journal-title":"Lancet Haematol"},{"key":"2872_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.bmt.1704518","volume":"34","author":"M Yanada","year":"2004","unstructured":"Yanada M, Emi N, Naoe T, Sakamaki H, Iseki T, Hirabayashi N, et al. Allogeneic myeloablative transplantation for patients aged 50 years and over. Bone Marrow Transpl. 2004;34:29\u201335.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR8","volume":"61","author":"Q Liu","year":"2025","unstructured":"Liu Q, Hu Z, Xu N, Jiang Y, Fan Z, Huang F, et al. Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial. Lancet Reg Health West Pac. 2025;61:101664.","journal-title":"Lancet Reg Health West Pac"},{"key":"2872_CR9","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/bmt.2017.182","volume":"52","author":"D Modi","year":"2017","unstructured":"Modi D, Deol A, Kim S, Ayash L, Alavi A, Ventimiglia M, et al. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. Bone Marrow Transpl. 2017;52:1530\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00277-020-04375-x","volume":"100","author":"K Laribi","year":"2021","unstructured":"Laribi K, Sobh M, Ghez D, Baugier de Materre A. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Ann Hematol. 2021;100:1359\u201376.","journal-title":"Ann Hematol"},{"key":"2872_CR11","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socie G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142\u201352.","journal-title":"Am J Hematol"},{"key":"2872_CR12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156\u201364.","journal-title":"Blood"},{"key":"2872_CR13","doi-asserted-by":"crossref","unstructured":"Cahn JY, Labopin M, Schattenberg A, Reiffers J, Willemze R, Zittoun R, et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). 1997;11:416\u20139.","DOI":"10.1038\/sj.leu.2400573"},{"key":"2872_CR14","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/S2352-3026(15)00148-9","volume":"2","author":"J Versluis","year":"2015","unstructured":"Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2:e427\u201336.","journal-title":"Lancet Haematol"},{"key":"2872_CR15","first-page":"334 e1","volume":"30","author":"E Abadir","year":"2024","unstructured":"Abadir E, Othman J, Kwan J, Gottlieb DJ, Kennedy GA, Bajel A, et al. Peripheral blood haploidentical allogeneic stem cell transplantation in older adults with acute myeloid leukemia and myelodysplastic syndromes demonstrates long-term survival, results from Australia and New Zealand transplant and cellular therapies. Transpl Cell Ther. 2024;30:334 e1\u2013e7.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41409-023-02134-w","volume":"59","author":"S Harbi","year":"2024","unstructured":"Harbi S, Brac de la Perri\u00e8re L, Bouchacourt B, Garciaz S, Pagliardini T, Calmels B, et al. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome. Bone Marrow Transpl. 2024;59:101\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1158\/1078-0432.CCR-23-3673","volume":"30","author":"A Bazarbachi","year":"2024","unstructured":"Bazarbachi A, Labopin M, Moukalled N, Kroger N, Rautenberg C, Schetelig J, et al. Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study. Clin Cancer Res. 2024;30:1778\u201387.","journal-title":"Clin Cancer Res"},{"key":"2872_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ajh.24270","volume":"91","author":"J Aoki","year":"2016","unstructured":"Aoki J, Kanamori H, Tanaka M, Yamasaki S, Fukuda T, Ogawa H, et al. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016;91:302\u20137.","journal-title":"Am J Hematol"},{"key":"2872_CR19","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878\u201387.","journal-title":"J Clin Oncol"},{"key":"2872_CR20","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Luis S, Berm\u00fadez A, Y\u00e1\u00f1ez San Segundo L, Baile Gonz\u00e1lez M, Marcos Asensio S, Esquirol A, et al. Allogeneic hematopoietic stem cell transplantation in elderly patients: the experience of the Grupo Espa\u00f1ol de Trasplante Hematopoy\u00e9tico y Terapia Celular. Transplantation. 2026;110:e243-e253","DOI":"10.1097\/TP.0000000000005446"},{"key":"2872_CR21","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1182\/bloodadvances.2021004435","volume":"6","author":"R Devillier","year":"2022","unstructured":"Devillier R, Forcade E, Garnier A, Guenounou S, Thepot S, Guillerm G, et al. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2022;6:1804\u201312.","journal-title":"Blood Adv"},{"key":"2872_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41375-020-1004-9","volume":"35","author":"AS Del Galy","year":"2021","unstructured":"Del Galy AS, Marouf A, Raffoux E, Robin M, Michonneau D, Sebert M, et al. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia. 2021;35:225\u20138.","journal-title":"Leukemia"},{"key":"2872_CR23","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","volume":"33","author":"C Ustun","year":"2019","unstructured":"Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33:2599\u2013609.","journal-title":"Leukemia"},{"key":"2872_CR24","first-page":"68","volume":"110","author":"D Niederwieser","year":"2025","unstructured":"Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, et al. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study. Haematologica. 2025;110:68\u201377.","journal-title":"Haematologica"},{"key":"2872_CR25","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s00277-021-04565-1","volume":"100","author":"T Heinicke","year":"2021","unstructured":"Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol. 2021;100:2387\u201398.","journal-title":"Ann Hematol"},{"key":"2872_CR26","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kroger","year":"2021","unstructured":"Kroger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J Clin Oncol. 2021;39:3318\u201327.","journal-title":"J Clin Oncol"},{"key":"2872_CR27","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","volume":"39","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50\u201375 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328\u201339.","journal-title":"J Clin Oncol"},{"key":"2872_CR28","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/JCO.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 Study. J Clin Oncol. 2023;41:4497\u2013510.","journal-title":"J Clin Oncol"},{"key":"2872_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/OP.23.00413","volume":"20","author":"W Saber","year":"2024","unstructured":"Saber W, Bansal A, Li L, Scott BL, Sangaralingham LR, Thao V, et al. Cost-effectiveness of reduced-intensity allogeneic hematopoietic cell transplantation for older patients with high-risk myelodysplastic syndrome: analysis of BMT CTN 1102. JCO Oncol Pr. 2024;20:572\u201380.","journal-title":"JCO Oncol Pr"},{"key":"2872_CR30","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41409-020-01064-1","volume":"56","author":"K Littlejohn","year":"2021","unstructured":"Littlejohn K, Tomlinson K, Armenian SH, Nakamura R, Sorror ML, McCune JS. Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. Bone Marrow Transpl. 2021;56:726\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR31","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41409-020-0934-1","volume":"55","author":"N Polverelli","year":"2020","unstructured":"Polverelli N, Tura P, Battipaglia G, Malagola M, Bernardi S, Gandolfi L, et al. Multidimensional geriatric assessment for elderly hematological patients (>\/=60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. Bone Marrow Transpl. 2020;55:2224\u201333.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087\u201392.","journal-title":"Lancet"},{"key":"2872_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/JCMA.0000000000000255","volume":"83","author":"SH Chien","year":"2020","unstructured":"Chien SH, Liu YC, Liu CJ, Ko PS, Wang HY, Hsiao LT, et al. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation. J Chin Med Assoc. 2020;83:238\u201344.","journal-title":"J Chin Med Assoc"},{"key":"2872_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41409-020-01032-9","volume":"56","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A, Tanaka M, et al. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transpl. 2021;56:387\u201394.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"2872_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/ageing\/afaa214","volume":"50","author":"LA Harvey","year":"2021","unstructured":"Harvey LA, Toson B, Norris C, Harris IA, Gandy RC, Close J. Does identifying frailty from ICD-10 coded data on hospital admission improve prediction of adverse outcomes in older surgical patients? A population-based study. Age Ageing. 2021;50:802\u20138.","journal-title":"Age Ageing"},{"key":"2872_CR37","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.jfma.2020.12.021","volume":"120","author":"SH Chien","year":"2021","unstructured":"Chien SH, Yao M, Li CC, Chang PY, Yu MS, Huang CE, et al. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. J Formos Med Assoc. 2021;120:2144\u201352.","journal-title":"J Formos Med Assoc"},{"key":"2872_CR38","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1200\/JCO.23.02631","volume":"42","author":"J Versluis","year":"2024","unstructured":"Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, et al. Risk stratification in older intensively treated patients with AML. J Clin Oncol. 2024;42:4084\u201394.","journal-title":"J Clin Oncol"},{"key":"2872_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2014.113571","volume":"100","author":"D Blaise","year":"2015","unstructured":"Blaise D, Devillier R, Lecoroller-Sorriano AG, Boher JM, Boyer-Chammard A, Tabrizi R, et al. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. Haematologica. 2015;100:269\u201374.","journal-title":"Haematologica"},{"key":"2872_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.103032","volume":"60","author":"AM de Souza","year":"2021","unstructured":"de Souza AM, Hamerschlak N, Kutner JM. Young haploidentical donor versus fully matched elderly donor: an observational study on patients aged 50 years or older underwent hematopoietic progenitor cells transplantation. Transfus Apher Sci. 2021;60:103032.","journal-title":"Transfus Apher Sci"},{"key":"2872_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41409-023-01984-8","volume":"58","author":"A Pruitt","year":"2023","unstructured":"Pruitt A, Gao F, De Togni E, Cochran H, Godbole S, Slade M, et al. Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2023;58:855\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"2872_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.bbmt.2018.02.002","volume":"24","author":"R Devillier","year":"2018","unstructured":"Devillier R, Legrand F, Rey J, Castagna L, Furst S, Granata A, et al. HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison. Biol Blood Marrow Transpl. 2018;24:1449\u201354.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2872_CR43","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41409-023-01931-7","volume":"58","author":"C Michel","year":"2023","unstructured":"Michel C, Robin M, Morisset S, Blaise D, Maertens J, Chevalier P, et al. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transpl. 2023;58:534\u201343.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR44","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.bbmt.2017.06.019","volume":"23","author":"M Slade","year":"2017","unstructured":"Slade M, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Romee R. Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transpl. 2017;23:1736\u201343.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2872_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13287-024-03640-4","volume":"15","author":"L Gao","year":"2024","unstructured":"Gao L, Yang L, Zhou S, Zhu W, Han Y, Chen S, et al. Allogenic hematopoietic stem cell transplantation outcomes of patients aged >\/= 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. Stem Cell Res Ther. 2024;15:24.","journal-title":"Stem Cell Res Ther"},{"key":"2872_CR46","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41375-024-02359-8","volume":"38","author":"S Piemontese","year":"2024","unstructured":"Piemontese S, Labopin M, Choi G, Broers AEC, Peccatori J, Meijer E, et al. Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide. Leukemia. 2024;38:2016\u201322.","journal-title":"Leukemia"},{"key":"2872_CR47","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1182\/bloodadvances.2024015582","volume":"9","author":"X Poire","year":"2025","unstructured":"Poire X, Labopin M, Polge E, Blaise D, Chevallier P, Maertens J, et al. Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia. Blood Adv. 2025;9:5192\u2013200.","journal-title":"Blood Adv"},{"key":"2872_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41409-018-0133-5","volume":"53","author":"M Debals-Gonthier","year":"2018","unstructured":"Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarie-Basset C, Chabannon C, et al. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transpl. 2018;53:1096\u2013104.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR49","first-page":"687 e1","volume":"30","author":"HT Kim","year":"2024","unstructured":"Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, et al. Comparison of older related versus younger unrelated donors for older recipients of allogeneic hematopoietic cell transplantation with acute myeloid leukemia or myelodysplastic syndrome: a large single-center analysis. Transpl Cell Ther. 2024;30:687 e1\u2013e13.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR50","first-page":"578 e1","volume":"29","author":"MB Abid","year":"2023","unstructured":"Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Allan D, Bredeson C, et al. Impact of donor age on allogeneic hematopoietic cell transplantation outcomes in older adults with acute myeloid leukemia. Transpl Cell Ther. 2023;29:578 e1\u2013e9.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR51","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","volume":"12","author":"EP Alyea","year":"2006","unstructured":"Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transpl. 2006;12:1047\u201355.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2872_CR52","first-page":"957","volume":"27","author":"MK Yong","year":"2021","unstructured":"Yong MK, Shigle TL, Kim YJ, Carpenter PA, Chemaly RF, Papanicolaou GA. American society for transplantation and cellular therapy series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transpl Cell Ther. 2021;27:957\u201367.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5045\/br.2022.2022194","volume":"57","author":"DH Kim","year":"2022","unstructured":"Kim DH, Seo J, Shin DY, Koh Y, Hong J, Kim I, et al. Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis. Blood Res. 2022;57:264\u201371.","journal-title":"Blood Res"},{"key":"2872_CR54","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.2147\/IDR.S392804","volume":"15","author":"W Chen","year":"2022","unstructured":"Chen W, Zhao Y, Luo Y, Yu J, Fu H, Lai X, et al. Clinical characteristics, microbiology, and risk factors for mortality of pre-engraftment and post-engraftment bloodstream infection in hematopoietic stem cell transplantation recipients. Infect Drug Resist. 2022;15:6893\u2013905.","journal-title":"Infect Drug Resist"},{"key":"2872_CR55","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2019.05.037","volume":"25","author":"O Ringden","year":"2019","unstructured":"Ringden O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2019;25:1975\u201383.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2872_CR56","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41409-022-01674-x","volume":"57","author":"R Devillier","year":"2022","unstructured":"Devillier R, Galimard JE, Labopin M, Blaise D, Raiola AM, Pavlu J, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transpl. 2022;57:1421\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR57","first-page":"323 e1","volume":"28","author":"S Kurosawa","year":"2022","unstructured":"Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, et al. Myeloablative versus reduced-intensity conditioning with fludarabine\/busulfan for myelodysplastic syndrome: a propensity score-matched analysis. Transpl Cell Ther. 2022;28:323 e1\u2013e9.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR58","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41409-025-02682-3","volume":"60","author":"N Henoun Loukili","year":"2025","unstructured":"Henoun Loukili N, Gras L, Koster L, Blaise D, Gedde-Dahl T, Maertens J, et al. Conditioning intensity in myelodysplastic patients aged \u2265 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2025;60:1487\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"2872_CR59","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/ajh.25636","volume":"94","author":"M Jentzsch","year":"2019","unstructured":"Jentzsch M, Dohring C, Linke R, Hille A, Grimm J, Ponisch W, et al. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. Am J Hematol. 2019;94:1344\u201352.","journal-title":"Am J Hematol"},{"key":"2872_CR60","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/bloodadvances.2022008706","volume":"7","author":"Y Akahoshi","year":"2023","unstructured":"Akahoshi Y, Tada Y, Sakaida E, Kusuda M, Doki N, Uchida N, et al. Novel risk assessment for the intensity of conditioning regimen in older patients. Blood Adv. 2023;7:4738\u201347.","journal-title":"Blood Adv"},{"key":"2872_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591363","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu S, Liu G, Liu J, Chen Q, Wang Z. Long-term outcomes of treosulfan- vs. busulfan-based conditioning regimen for patients with myelodysplastic syndrome and acute myeloid leukemia before hematopoietic cell transplantation: a systematic review and meta-analysis. Front Oncol. 2020;10:591363.","journal-title":"Front Oncol"},{"key":"2872_CR62","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Remenyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28\u2013e39.","journal-title":"Lancet Haematol"},{"key":"2872_CR63","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41409-024-02241-2","volume":"59","author":"DW Beelen","year":"2024","unstructured":"Beelen DW, Iacobelli S, Koster L, Eikema DJ, van Biezen A, Stolzel F, et al. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients\u2014a clinical trial to registry data comparison. Bone Marrow Transpl. 2024;59:670\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR64","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12185-021-03188-6","volume":"114","author":"C Ohwada","year":"2021","unstructured":"Ohwada C, Yamazaki S, Shono K, Kayamori K, Hino Y, Oshima-Hasegawa N, et al. Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML\/MDS patients as a conditioning regimen for allogeneic stem cell transplantation. Int J Hematol. 2021;114:664\u201373.","journal-title":"Int J Hematol"},{"key":"2872_CR65","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1182\/bloodadvances.2023010850","volume":"7","author":"UR Popat","year":"2023","unstructured":"Popat UR, Pasvolsky O, Bassett R Jr, Mehta RS, Olson A, Chen J, et al. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023;7:6196\u2013205.","journal-title":"Blood Adv"},{"key":"2872_CR66","first-page":"913 e1","volume":"27","author":"RS Mehta","year":"2021","unstructured":"Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, et al. Myeloablative fractionated busulfan with fludarabine in older patients: long-term disease-specific outcomes of a prospective phase II clinical trial. Transpl Cell Ther. 2021;27:913 e1\u2013e12.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR67","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41409-019-0594-1","volume":"54","author":"A Bacigalupo","year":"2019","unstructured":"Bacigalupo A, Maria Raiola A, Dominietto A, Di Grazia C, Gualandi F, Lint MTV, et al. Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. Bone Marrow Transpl. 2019;54:708\u201312.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR68","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","volume":"58","author":"R Dulery","year":"2023","unstructured":"Dulery R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transpl. 2023;58:386\u201392.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR69","first-page":"536 e1","volume":"30","author":"MQ Salas","year":"2024","unstructured":"Salas MQ, Alfaro-Moya T, Atenafu EG, Datt Law A, Lam W, Pasic I, et al. Outcomes of antithymocyte globulin-post-transplantation cyclophosphamide-cyclosporine-based versus antithymocyte globulin-based prophylaxis for 10\/10 HLA-matched unrelated donor allogeneic hematopoietic cell transplantation. Transpl Cell Ther. 2024;30:536 e1\u2013e13.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR70","first-page":"587 e1","volume":"28","author":"G Battipaglia","year":"2022","unstructured":"Battipaglia G, Labopin M, Blaise D, Diez-Martin JL, Bazarbachi A, Vitek A, et al. Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone in acute myelogenous leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transpl Cell Ther. 2022;28:587 e1\u2013e7.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR71","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/bjh.70050","volume":"207","author":"A Capes","year":"2025","unstructured":"Capes A, Mooyaart JE, Blaise D, Bramanti S, Kwon M, Mohty M, et al. Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: a retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2025;207:1529\u201337.","journal-title":"Br J Haematol"},{"key":"2872_CR72","first-page":"794","volume":"30","author":"LM Morsink","year":"2024","unstructured":"Morsink LM, Hazenberg CLE, Choi G, de Groot MR, Biswana A, Bellido M, et al. Improved outcome of allogeneic transplantation in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide and reduced duration of immune suppression. Transpl Cell Ther. 2024;30:794\u2013807.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR73","first-page":"71","volume":"29","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, et al. Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transpl Cell Ther. 2023;29:71\u201381.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR74","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-020-01017-7","volume":"14","author":"L Xuan","year":"2021","unstructured":"Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14:4.","journal-title":"J Hematol Oncol"},{"key":"2872_CR75","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38:4249\u201359.","journal-title":"J Clin Oncol"},{"key":"2872_CR76","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","volume":"4","author":"B Oran","year":"2020","unstructured":"Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4:5580\u20138.","journal-title":"Blood Adv"},{"key":"2872_CR77","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, et al. Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024;8:978\u201390.","journal-title":"Blood Adv"},{"key":"2872_CR78","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1200\/JCO.22.00181","volume":"40","author":"A Mishra","year":"2022","unstructured":"Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40:3985\u201393.","journal-title":"J Clin Oncol"},{"key":"2872_CR79","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10:e600\u2013e11.","journal-title":"Lancet Haematol"},{"key":"2872_CR80","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766\u201375.","journal-title":"J Clin Oncol"},{"key":"2872_CR81","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","volume":"11","author":"S Pagliuca","year":"2024","unstructured":"Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11:e448\u2013e58.","journal-title":"Lancet Haematol"},{"key":"2872_CR82","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","volume":"59","author":"L Yang","year":"2024","unstructured":"Yang L, Lai X, Yang T, Lu Y, Liu L, Shi J, et al. Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Bone Marrow Transpl. 2024;59:85\u201392.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41409-022-01839-8","volume":"58","author":"N Santoro","year":"2023","unstructured":"Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, et al. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transpl. 2023;58:54\u201360.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","volume":"36","author":"SO Ciurea","year":"2022","unstructured":"Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, et al. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022;36:155\u201364.","journal-title":"Leukemia"},{"key":"2872_CR85","first-page":"1206 e1","volume":"30","author":"A Merino","year":"2024","unstructured":"Merino A, Brunstein CC, Shanley R, Rashid F, Wangen R, Bachanova V, et al. N-803, an IL-15 superagonist complex as maintenance therapy after allogeneic donor stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome; A phase 2 trial. Transpl Cell Ther. 2024;30:1206 e1\u2013e12.","journal-title":"Transpl Cell Ther"},{"key":"2872_CR86","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s41409-024-02327-x","volume":"59","author":"J Shoag","year":"2024","unstructured":"Shoag J, Rotz SJ, Hanna R, Buhtoiarov I, Dewey EN, Bruckman D, et al. Disparities in access to hematopoietic cell transplant persist at a transplant center. Bone Marrow Transpl. 2024;59:1258\u201364.","journal-title":"Bone Marrow Transpl"},{"key":"2872_CR87","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1111\/ajco.13797","volume":"19","author":"AM Belyaev","year":"2023","unstructured":"Belyaev AM, Lewis C, Doocey R, Bergin CJ. The association of socioeconomic deprivation with access and survival after hematopoietic stem cell transplantation in New Zealand. Asia Pac J Clin Oncol. 2023;19:e89\u2013e95.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2872_CR88","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.3399\/bjgp18X700241","volume":"69","author":"J Travers","year":"2019","unstructured":"Travers J, Romero-Ortuno R, Bailey J, Cooney MT. Delaying and reversing frailty: a systematic review of primary care interventions. Br J Gen Pr. 2019;69:e61\u2013e9.","journal-title":"Br J Gen Pr"},{"key":"2872_CR89","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(19)31785-4","volume":"394","author":"E Dent","year":"2019","unstructured":"Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty: opportunities, challenges, and future directions. Lancet. 2019;394:1376\u201386.","journal-title":"Lancet"},{"key":"2872_CR90","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1200\/JCO-25-00713","volume":"43","author":"JM Jacobs","year":"2025","unstructured":"Jacobs JM, Traeger L, Freese M, Barata A, Newcomb R, Rabideau D, et al. BMT-CARE App: a randomized controlled trial of a psychosocial digital application for caregivers of patients undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2025;43:2265\u201375.","journal-title":"J Clin Oncol"},{"key":"2872_CR91","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"SM Devine","year":"2015","unstructured":"Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33:4167\u201375.","journal-title":"J Clin Oncol"},{"key":"2872_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639502","volume":"11","author":"YQ Sun","year":"2021","unstructured":"Sun YQ, Han TT, Wang Y, Yan CH, Wang FR, Wang ZD, et al. Haploidentical stem cell transplantation with a novel conditioning regimen in older patients: a prospective single-arm phase 2 study. Front Oncol. 2021;11:639502.","journal-title":"Front Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02872-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:03:27Z","timestamp":1783605807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02872-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02872-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}